Watertown, MA (USA) – September 28, 2020: Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), today announced the mechanical completion of GMP suites at its Watertown, MA commercial-ready facility. Arranta is investing more than $100M in 2020 to establish a state of the art, multi-product, commercial-ready manufacturing facility that will supply…
Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), today announced the addition of Shailesh Maingi to Arranta’s board as an Independent Director. Shailesh Maingi is the founder and CEO of Kineticos Life Sciences, a boutique advisory focused on strategy, licensing and commercial product launch that he established in 2007. In 2019 he founded the…
Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), today announced the completion of its microbiome process development lab expansion project and a commitment to add additional early- clinical GMP capacity at its Center of Excellence for Microbiome Process Development and Early Clinical Supply. Arranta has completed the expansion of purpose-built microbiome…
Watertown, MA – January 28, 2020: Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), announced today the strengthening of its senior leadership team with the addition of David Stevens as Chief Operations Officer and Jason Rahal as Senior Vice President of Business Development. Arranta has committed $100M to build end-to-end capacity…
Watertown, MA – November [13], 2019: Arranta Bio (“Arranta”) announced today the acquisition of Captozyme™, and with it the establishment of Arranta’s Center of Excellence for process and analytical development and early clinical supply for microbiome clients with the transfer of the Captozyme team and facilities in Gainesville, FL to Arranta. Formed in 2009, Captozyme has…
Watertown, MA – October 29, 2019: Arranta Bio (“Arranta”) announced today the completion of an $82 million funding round and a strategic partnership with Thermo Fisher Scientific. Formed in May 2019, Arranta’s goal is to be the best-in-class microbiome contract development and manufacturing organization (CDMO). The business provides live biopharmaceutical products (LBPs) for microbiome pioneers by…
